NAD on breast enhancement tablets
This article was originally published in The Tan Sheet
Executive Summary
Ad watchdog group recommends Dream Products discontinue claims its Breast Enhancer Tablets offer an alternative to surgery or push-up bras, recent case report states. Wellquest International challenged Dream's print, Internet ad claims, such as "Larger shapelier breasts...without surgery" and "Clinically formulated to increase your bust size," describing claims as "false, misleading and unsubstantiated." Wellquest also asserted Dream had not provided clinical research on Breast Enhancer's exact formulation, which includes saw palmetto, wild yam, damiana, dong quai, fenugreek, black cohosh, blessed thistle and rice flour. CBBB division agrees, noting Dream's performance, health-related claims "were not supported by competent and scientific evidence." Dream says it will modify future ads...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.